Findings from a clinical trial comparing liraglutide 1.8mg (Victoza) and sitagliptin (100mg), both in combination with metformin, demonstrated that switching from sitagliptin to liraglutide provided superior HbA1c reductions versus continuing with sitagliptin treatment in adults with type 2 diabetes.
These results from the LIRA-SWITCH trial were presented at the Endocrine Society’s 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US.
The 26-week LIRA-SWITCH trial assessed the efficacy and safety of liraglutide as an add on to metformin in 407 adults with type 2 diabetes who switched from sitagliptin. Of the 407 adults uncontrolled on sitagliptin (HbA1c 7.5–9.5%) at week 26, those who switched to liraglutide (n=203) achieved a superior reduction in HbA1c versus those who continued their sitagliptin treatment (n=204) (−1.14% vs −0.54%; estimated treatment difference [ETD] −0.61%, 95% confidence interval [CI]: −0.82 to −0.40, p<0.0001).
Additionally, adults who switched to liraglutide experienced significantly greater body weight reductions versus those who continued with their sitagliptin dose.
Dr Maximo Maislos, Director of Western Negev Mobile Diabetes Clinic Program, and Diabetes and Metabolism, Ben-Gurion University FOHS, Beer Sheva-Israel and investigator of the LIRA-SWITCH trial, said: "The LIRA-SWITCH trial results provide valuable insight that adults uncontrolled on sitagliptin may achieve a superior HbA1c reduction with liraglutide 1.8 mg vs continuing on sitagliptin treatment. These findings are valuable as there is limited clinical evidence to guide treatment strategy when people with type 2 diabetes are uncontrolled on second-line therapy."
The 26-week trial was a randomised, double-blind, double-dummy, active-controlled trial involving 407 adults with type 2 diabetes not achieving adequate glycaemic control on sitagliptin as add-on to metformin. Trial participants were previously treated with stable doses of sitagliptin (100mg daily) and metformin (≥1500mg daily or maximum tolerated dose ≥1000mg daily) for ≥90 days. Participants were randomised 1:1 to switch to liraglutide 1.8mg or continue sitagliptin 100mg, both in combination with metformin.